Literature DB >> 2937795

Quantification of Neuroreceptors in the living human brain. II. Inhibition studies of receptor density and affinity.

D F Wong, A Gjedde, H N Wagner, R F Dannals, K H Douglass, J M Links, M J Kuhar.   

Abstract

A method for estimating receptor density (Bmax) in the living human brain by positron emission tomography was exemplified by a ligand, 3-N-[11C]methylspiperone ([11C]NMSP), that binds to D2 dopamine receptors with high affinity. The ligand binds essentially irreversibly (i.e., with very little dissociation) to the receptors during the 2-h scanning period. Transfer constants were estimated at steady state. In a previous article, we presented a method for the determination of k3, the rate of binding of the labeled ligand. In the present work, we varied k3 by reducing the number of available receptors with a previously administered receptor blocking agent, haloperidol. We calculated a receptor density of 9.2 pmol g-1 in the caudate nucleus of four normal volunteers, and an inhibitory constant of haloperidol of 1.4 nM by comparing tracer accumulation in the absence and the presence of the blocking agent. The values agreed with measurements of NMSP receptor density and haloperidol inhibitory potency in vitro in brain homogenates from human autopsy material.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2937795     DOI: 10.1038/jcbfm.1986.28

Source DB:  PubMed          Journal:  J Cereb Blood Flow Metab        ISSN: 0271-678X            Impact factor:   6.200


  17 in total

Review 1.  Uses and limitations of positron emission tomography in clinical pharmacokinetics/dynamics (Part II).

Authors:  L L Ponto; J A Ponto
Journal:  Clin Pharmacokinet       Date:  1992-04       Impact factor: 6.447

Review 2.  Positron emission tomography applied in the study of pituitary adenomas.

Authors:  C Muhr; M Bergström
Journal:  J Endocrinol Invest       Date:  1991-06       Impact factor: 4.256

Review 3.  Effects of long-term administration of antidepressants and neuroleptics on receptors in the central nervous system.

Authors:  G B Baker; A J Greenshaw
Journal:  Cell Mol Neurobiol       Date:  1989-03       Impact factor: 5.046

4.  Analysis of three- and four-compartment models for in vivo radioligand-neuroreceptor interaction.

Authors:  B R Zeeberg; H N Wagner
Journal:  Bull Math Biol       Date:  1987       Impact factor: 1.758

5.  Theoretical effects of radioligand diffusional gradients and microscopic neuroreceptor distribution in in vivo kinetic studies.

Authors:  B R Zeeberg; R C Reid; K A Murphy; R C Reba
Journal:  Bull Math Biol       Date:  1988       Impact factor: 1.758

Review 6.  Pharmacokinetic imaging: a noninvasive method for determining drug distribution and action.

Authors:  Alan J Fischman; Nathaniel M Alpert; Robert H Rubin
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

7.  Evaluation of SCH 39166 as PET ligand for central D1 dopamine receptor binding and occupancy in man.

Authors:  P Karlsson; G Sedvall; C Halldin; C G Swahn; L Farde
Journal:  Psychopharmacology (Berl)       Date:  1995-10       Impact factor: 4.530

8.  Persistent psychosis after reduction in pre- and post-synaptic dopaminergic function.

Authors:  A Wolkin; E Duncan; M Sanfilipo; S Wieland; T B Cooper; J Rotrosen
Journal:  J Neural Transm Gen Sect       Date:  1994

9.  Reversible inhibitors of monoamine oxidase-A (RIMAs): robust, reversible inhibition of human brain MAO-A by CX157.

Authors:  Joanna S Fowler; Jean Logan; Albert J Azzaro; Robert M Fielding; Wei Zhu; Amy K Poshusta; Daniel Burch; Barry Brand; James Free; Mahnaz Asgharnejad; Gene-Jack Wang; Frank Telang; Barbara Hubbard; Millard Jayne; Payton King; Pauline Carter; Scott Carter; Youwen Xu; Colleen Shea; Lisa Muench; David Alexoff; Elena Shumay; Michael Schueller; Donald Warner; Karen Apelskog-Torres
Journal:  Neuropsychopharmacology       Date:  2009-11-04       Impact factor: 7.853

Review 10.  PET in clinical oncology.

Authors:  R A Hawkins; M E Phelps
Journal:  Cancer Metastasis Rev       Date:  1988-06       Impact factor: 9.264

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.